retatrutide study near me STUDY: Novel “Triagonist” Resolved Steatosis in Over 85% of Patients with MASLD and Obesity Triple hormone receptor agonist retatrutide

Shivaswamy V, Boerner B, Larsen J

NICE guidance (NG28) recommends GLP-1 receptor agonists as treatment options for adults with type 2 diabetes when metformin and other oral therapies have not achieved adequate glycaemic control, or when there are specific clinical considerations such as significant obesity or high cardiovascular risk

GLP-1 medications carry important warnings and contraindications, including a boxed warning for thyroid C-cell tumors in rodents (contraindicated in patients with personal/family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2)

A study shows that GLP-1 receptor agonists show a notably reduced incidence of primary open-angle glaucoma (POAG), ocular hypertension, and the requirement for first-line glaucoma treatments compared to metformin in individuals with type 2 diabetes (80)

This means that your dosing schedule for weight loss might be different from others, so you will work with your healthcare provider to find the right therapeutic dose for you

A solid protocol is not one-size-fits-all